Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 12, p. 4001, doi. 10.1007/s00262-023-03534-z

By:

• Wahid, Mussarat;
• Pratoomthai, Benjamart;
• Egbuniwe, Isioma U.;
• Evans, Hannah R.;
• Babaei-Jadidi, Roya;
• Amartey, Jason O.;
• Erdelyi, Viola;
• Yacqub-Usman, Kiren;
• Jackson, Andrew M.;
• Morris, Jonathan C.;
• Patel, Poulam M.;
• Bates, David O.

Publication type:

Article